Hakan S. Edstrom, the President and COO of MannKind Corporation (MNKD), Interviews with The Wall Street Transcript

Wall Street Transcript

67 WALL STREET, New York - April 25, 2014 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Biotechnology and Pharmaceutical Companies Valuation - Genetic and Cell Therapies

Companies include: MannKind Corp. (MNKD) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President and COO of MannKind Corporation (MNKD) discusses company strategy and the outlook for this vital industry:

TWST: Can you give us an overview of MannKind's business?

Mr. Edstrom: MannKind Corporation is a pharmaceutical company focused on discovery, development and commercialization of products focused on diseases such as diabetes - which is certainly our focus right now. We were incorporated back in 1991. I'm sitting at our corporate headquarters in Valencia, California; the clinical resource, development, regulatory and some of the commercial operations are located in Paramus, New Jersey; and a big manufacturing site and operations are located in Danbury, Connecticut. So we are geographically spread out.

As most people know, our lead product is AFREZZA, which is a novel, ultra-rapid-acting mealtime or prandial insulin that we developed for the treatment of patients with Type I and Type II diabetes. It's a combination of the drug insulin, a white powder and a small discreet inhaler that's used to inhale the powder into the deep lung. Patients inhale AFREZZA at the start of a meal, and then it dissolves rapidly into the deep lung. So you have really peak concentration of the insulin in the blood within 12 to 15 minutes, and that's a very unique aspect of AFREZZA as compared to other so-called rapid-acting insulins, which take 45 to 90 minutes, or even regular human injected insulin, which is 90 to 150 minutes. This synchronization of the peak insulin levels of AFREZZA in the blood coincides very well with the digestion of the meal and has some significant beneficial therapeutic benefits associated with it.

If we go to the most recent events that have been noteworthy for MannKind, on April 1, we presented to the FDA's Endocrinologic and Metabolic Drugs Advisory Committee in Washington, D.C. The committee voted 13 to one to recommend marketing approval for AFREZZA for Type I patients, and 14 to zero in terms of a recommendation to approve AFREZZA for glycemic control in patients with Type II diabetes. So that was a very, very encouraging outcome.

TWST: Your stock jumped quite a bit after that, I think it was up about 74% after that announcement.

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (1)